STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
PBYI PUMA BIOTECHNOLOGY INCORPORATED StockScouter® Report
6
StockScouter® Score
PUMA BIOTECHNOLOGY INCORPORATED, a small cap value company in the healthcare sector, is expected to slightly outperform the market over the next six months with less than average risk
10 is the best possible rating. Learn more.
Summary
Positives
- The enterprise value-to-sales ratio is lower than the average for comparably-sized companies in the StockScouter universe. Positive
- Moving average analysis for PBYI suggests strong price movement over the medium term. Positive
Concerns
- The most recent quarterly earnings report was significantly lower than analysts’ consensus forecast. Negative
- One or more analysts has modestly decreased quarterly earnings estimates for PBYI. Negative
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that small cap stocks will be neutral, value stocks will be neutral, and healthcare stocks will be neutral.
Expected Risk/Return
Core Model Grades
D
C
B
B